GHK-Cu vs TB-500
GHK-Cu and TB-500 are both studied in repair and recovery contexts, but they operate through entirely different biological mechanisms. GHK-Cu is a naturally occurring copper tripeptide that works at the level of the extracellular matrix, primarily influencing fibroblasts, collagen synthesis, and oxidative defense systems. TB-500 is a synthetic analog of the actin-binding region of Thymosin Beta-4, acting systemically through G-actin sequestration and cellular migration pathways. Researchers selecting between them typically focus on whether the study targets local matrix repair or systemic recovery signaling.
GHK-Cu
Copper-binding tripeptide (Gly-His-Lys plus Cu2+)
TB-500
Synthetic Tβ4 fragment (17 amino acids)
At a Glance
Key research profiles for each compound.
GHK-Cu
Copper-binding tripeptide studied for ECM remodeling and collagen synthesis
Class
Copper-binding tripeptide (Gly-His-Lys plus Cu2+)
Mechanism
Copper ion delivery, collagen upregulation, MMP modulation
Half-Life
Rapidly cleared, endogenous plasma peptide
Research Area
Skin, collagen, ECM, wound healing
- Investigated for collagen I and III synthesis regulation in fibroblast cultures
- Studied for copper-dependent antioxidant enzyme activity and oxidative defense
- Documented effects on wound healing and extracellular matrix turnover in vitro
- Examined for broad gene expression modulation across skin and repair biology
TB-500
Thymosin Beta-4 fragment studied for systemic recovery and cellular migration
Class
Synthetic Tβ4 fragment (17 amino acids)
Mechanism
Actin sequestration, G-actin binding, cell migration regulation
Half-Life
Estimated 6 to 8 hours in preclinical models
Research Area
Systemic recovery, cardiovascular, musculoskeletal
- Studied for G-actin sequestration and cellular migration in vitro
- Investigated for angiogenesis and vascular repair in preclinical injury models
- Examined for anti-inflammatory signaling in musculoskeletal tissue models
- Explored for cardiac protection and repair in ischemic injury models
Side-by-Side Comparison
Key research parameters compared directly.
| Feature | GHK-Cu | TB-500 |
|---|---|---|
| Peptide Class | Copper-binding tripeptide (3 AA) | Tβ4 synthetic fragment (17 AA) |
| Primary Mechanism | Copper delivery, collagen synthesis, MMP modulation | Actin sequestration, G-actin binding |
| Research Target | Fibroblasts, ECM, skin, wound beds | Systemic: muscle, cardiac, vascular |
| Molecular Weight | ~340 Da (plus Cu2+) | ~2,112 Da |
| Natural Occurrence | Endogenous in human plasma and urine | Synthetic analog of endogenous Tβ4 region |
| Systemic vs Local | Primarily local, tissue-level action | Documented systemic distribution in models |
| Estimated Half-Life | Short, rapidly cleared | 6 to 8 hours (preclinical) |
| Anti-Aging Relevance | Collagen decline, ECM aging, antioxidant research | Recovery, cardiovascular aging models |
Research Deep-Dive
GHK-Cu
GHK-Cu's research profile centers on the extracellular matrix and fibroblast-mediated repair processes. As an endogenous peptide that declines significantly between the ages of 20 and 60, it has been examined as a modulator of age-related ECM degradation. In fibroblast cultures, GHK-Cu upregulates collagen Type I and III synthesis, promotes glycosaminoglycan production, and modulates matrix metalloproteinase activity. Its copper-binding function also contributes to superoxide dismutase activity, making it relevant to oxidative stress research. The compound is also notable for influencing the expression of over 4,000 human genes in cell-based studies, spanning inflammation, tissue repair, and antioxidant defense pathways.
View GHK-Cu →TB-500
TB-500 derives its mechanism from the ADS (actin-binding) motif of Thymosin Beta-4, an endogenous protein expressed in nearly all nucleated mammalian cells. By sequestering G-actin, TB-500 regulates the availability of actin monomers for polymerization, a process central to cell motility and wound closure. Its systemic distribution following administration has been documented in animal models, distinguishing it from locally acting matrix peptides like GHK-Cu. Preclinical research has examined TB-500 in cardiac repair following ischemia, musculoskeletal recovery, and anti-inflammatory modulation in tissue injury contexts.
View TB-500 →Research Context
GHK-Cu and TB-500 are occasionally studied in combination in wound healing and recovery models, where both ECM remodeling and cellular migration contribute to the repair process. Researchers designing protocols for skin or connective tissue repair may include GHK-Cu for the matrix and structural side while relying on TB-500 for the cellular motility and systemic recovery signaling. Their non-overlapping mechanisms and different molecular targets make them complementary rather than redundant in multi-compound research designs.
Frequently Asked Questions
Related Comparisons
Research Use Cases
Research Stacks
Source Both Compounds
GHK-Cu and TB-500 are both available from Spartan Peptides at ≥98% HPLC-verified purity. Domestic US supply, same-day dispatch before 2 PM. All products for in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.